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A B S T R A C T
Background: Antidepressant use during pregnancy has increased over the last decades, while safety has been
under debate. Our aim was to measure the international prevalence of antidepressant use before, during, and
after pregnancy and examine timing, type of prescriptions and geographic variability.
Methods: We searched Embase, Medline Ovid, Web of Science, Cochrane Central and Google Scholar from their
inception until February 19, 2019. We determined pooled prevalence estimates of antidepressants before,
during, and after pregnancy, as well as stratified according to substantive variables.
Results: We identified 40 cohorts from 15 countries, together reporting on 14,072,251 pregnancies. Included
studies had a low risk of bias, often reporting on large representative cohorts. Selective serotonin reuptake
inhibitors (SSRIs) were the most commonly used antidepressants during pregnancy, with an international pre-
valence estimate of 3.0% (95%CI 2.3;3.7). While Europe and Australasia had pooled prevalence estimates of
1.6% and 1.3% respectively, Northern America had a prevalence estimate of 5.5% (Q-value = 126.19; df = 2; p-
value<0.01). Highest SSRI prevalence rates were found for sertraline (1.10%), followed by citalopram and
fluoxetine (0.77% and 0.76% respectively) (Q-value = 121.25; df = 5; p-value<0.01). Qualitative analysis
indicated an increase in antidepressant use over subsequent calendar years.
Limitations: Substantial heterogeneity remained unaccounted for throughout the analyses, even after accounting
for hypothetical contributors.
Conclusions: This meta-analysis revealed substantial regional differences in antidepressant use around preg-
nancy, which could be due to variability in prescription behavior, healthcare seeking behavior and organization
of healthcare. There is an urgent need for evidence on effectiveness, benefit, and harm of antidepressants during
pregnancy to guide clinical practice.
1. Introduction
Prescribed medication use during pregnancy is common, with
overall estimates in developed countries ranging from 27% to 93%,
excluding vitamins and minerals (Daw et al., 2011). Over the last
decades, this use of prescription medication during pregnancy has in-
creased by more than 60% (Mitchell et al., 2011), and antidepressants
greatly contribute to this increase (Andrade et al., 2016; Charlton et al.,
2015; Cooper et al., 2007). In the general population, antidepressants
are now among the top three most commonly prescribed therapeutic
drug classes in the United States (Pratt et al., 2017). Antidepressants
showed the largest increase in prescriptions during pregnancy over
time, compared to other drugs associated with potential harmful neo-
natal effects (van Gelder et al., 2014).
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The use of antidepressants during pregnancy has been under debate,
because evidence on adverse fetal and child outcomes is inconclusive
(Simoncelli et al., 2010). Studies have found associations of maternal
antidepressant use with increased risks for cardiovascular malforma-
tions (Grigoriadis et al., 2013b), persistent pulmonary hypertension of
the neonate (Kieler et al., 2012), poor neonatal adaptation
(Grigoriadis et al., 2013a), preterm delivery and lower birth weight
(Ross et al., 2013), altered fetal brain development (Lugo-
Candelas et al., 2018), and psychiatric disorders in the offspring such as
mood disorders, autism spectrum disorders and behavioral disorders
including ADHD (Liu et al., 2017). Other studies failed to find these
increased risks or observed only modest effects (Furu et al., 2015;
Huybrechts et al., 2015; Hviid et al., 2013). Since studies on anti-
depressants in pregnancy are not typically randomized, it is often dif-
ficult to determine if reported adverse outcomes associated with anti-
depressants are related to the medication itself, the underlying maternal
mental illness, genetic risk differences between women with and
without mental illness, other confounding exposures such as alcohol,
smoking, substance abuse, nutrition, and other medications, or socio-
economic differences between cohorts. As a result, the risk of these
medications is not definitively established. Coupled with the lack of
robust data on alternative therapies while discontinuing anti-
depressants in pregnancy, both women and clinicians lack clear gui-
dance whether they should continue antidepressants during pregnancy
or not. Consequently, 50% of women decide to discontinue their anti-
depressants, either before or during pregnancy (Charlton et al., 2015;
Hanley and Mintzes, 2014; Molenaar et al., 2019).
Limited data suggest that prescription rates and antidepressants use
vary by country and study setting (Charlton et al., 2015). We performed
a systematic review and meta-analysis to examine international pre-
valence rates and patterns of antidepressant use before, during, and
after pregnancy. We explored use in the different trimesters, examined
geographical differences in prescription patterns and examined pre-
valence trends over time.
2. Methods
2.1. Literature search
This systematic review and meta-analysis was conducted and re-
ported in line with the PRISMA guidelines (Liberati et al., 2009). The
protocol was registered in PROSPERO (CRD42018116978). All large
databases, including embase.com, Medline Ovid, Web of Science, Co-
chrane Central and Google Scholar were searched by a medical in-
formation specialist from inception to February 19, 2019, using search
terms describing types of antidepressants, the target population and
type of study (full search strategy available in the Online Resource).
2.2. Eligibility criteria
Studies were eligible if they were peer-reviewed, written in English,
and if they described a population of women using antidepressants ei-
ther the year before pregnancy, during pregnancy, or the first post-
partum year. The following groups of antidepressants were included:
selective serotonin reuptake inhibitors (SSRIs), serotonin and nor-
epinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants
(TCAs), monoamine oxidase inhibitors (MAOIs), and other anti-
depressants (e.g. tetracyclics). To avoid unreliable comparisons, studies
that did not specify on which groups of antidepressants they reported
were excluded, as underreporting could not be ruled out (e.g. a study
reporting on ‘antidepressants’ could be a study only including TCAs,
thereby leading to a gross underreporting of the prevalence of anti-
depressants in the perinatal period). All observational studies reporting
the antidepressant prevalence in a certain time period with a known
cohort size or reporting a numerator and denominator were included.
We excluded case-control studies, case reports, case series, reviews,
conference abstracts, and studies reporting on antidepressant use
without specifying the country or perinatal phase. We also excluded
studies focused on specific subpopulations (population not suitable)
instead of general prevalence of antidepressant use (e.g. antidepressant
use in pregnant women suffering from a major depressive disorder, or
antidepressant use in a population of women with birth defects in the
offspring), as we were interested in the population-based prevalence
rates.
2.3. Study selection and data extraction
Duplicates were screened and removed with the citation manager
EndNote. Two reviewers (NMM, BB) independently screened the titles
and abstracts and assessed the full text of potential eligible studies.
When multiple papers reported on the same cohort, the paper with
highest level of detail was included (e.g. a paper reporting on multiple
antidepressant subgroups). Two reviewers (NMM, BB) independently
extracted data using a standardized data extraction form. We extracted
the number of pregnancies aided by antidepressant use specified to type
of antidepressant and perinatal phase (numerator) and the total number
of pregnancies in the corresponding perinatal phase (denominator) for
the entire cohort and, when available, per subsequent calendar years
for time trend analysis. We report whether the outcome describes all
pregnancies or life births only and whether multiple pregnancies and
consecutive pregnancies were included. Additionally, data was ex-
tracted regarding the study period, geographic location, type of study
(prospective, retrospective), in- and exclusion criteria, and definition of
antidepressant use (dispensing, prescription, self-report).
Disagreements between reviewers were reconciled among NMM, BB
and AMK.
2.4. Quality assessment
The quality of the studies related to antidepressant prevalence was
assessed informed by the Joanna Briggs Institute's critical appraisal
checklist for studies reporting prevalence data (Munn et al., 2015,
2014). Potential bias with regard to the following quality criteria was
assessed: 1) was the sample frame appropriate to address the target
population, 2) were study participants sampled in an appropriate way,
3) was the sample size adequate, 4) were study subjects and setting
described in detail, and 5) was the response rate adequate. The sample
frame was deemed appropriate when the sample was a valid re-
presentation of the general population of the country where the study
was performed (e.g. birth registers covering the entire country are ap-
propriate, while a cohort from a single general hospital is not). There
was an appropriate sampling method when in- and exclusion criteria
were not restrictive. Sample size was considered adequate when larger
than 2000 participants (Naing et al., 2006).
2.5. Procedure for meta-analyses
Data analysis was carried out in STATA (version 15, STATA
Corporation, College Station, TX, USA) using metaprop procedures
(Nyaga et al., 2014). Overall pooled estimates were calculated with
inverse-variance weights obtained from the random-effects model using
the method of DerSimonian and Laird. Confidence intervals of the un-
ique studies were computed with the exact method. We calculated an
overall prevalence and 95% Confidence Interval (CI) per anti-
depressant, per perinatal phase (before, during, after), and per geo-
graphic region. Subgroup differences were tested using the random-
effects model. Random-effects was chosen over fixed-effects analysis as
substantial heterogeneity was expected (Munn et al., 2015). We re-
ported Cochran's Q-, I2-statistics and significance levels. We also
decided to calculate 95% prediction intervals using the method sug-
gested by Higgins et al. given the substantial heterogeneity found
(Higgins et al., 2009). We qualitatively reviewed the impact of time on
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prevalence rates due to limited reported prevalence rates per calendar
year. Additional time trend analysis using random-effects meta-regres-
sion analysis can be found in the Online Resource.
Sensitivity analysis were used to assess the robustness of our find-
ings and to explore potential sources of heterogeneity. Per type of an-
tidepressant we estimated the overall prevalence using both random-
and fixed-effect calculation to evaluate the impact of the estimation
method. We then examined prevalence rates of SSRIs during pregnancy
in more detail, as that was the most frequently studied and most
commonly used type of antidepressant. We estimated the impact of
methodological factors, study quality and bias on the prevalence of
SSRI use during pregnancy. We reported Cochran's Q and significance
levels.
We used funnel plots to visually assess the presence of small-study
effects per pregnancy phase among studies reporting on SSRI use, and
Egger's regression-based test for formal assessment (results in Online
Resource).
3. Results
3.1. Selection of studies
The literature search produced a set of 6618 articles after de-du-
plication, which were then reviewed based on titles and abstracts by
two independent reviewers, resulting in an initial selection of 354 ar-
ticles. After full-text assessment of the 354 articles, 39 articles, re-
porting on 40 cohorts (Charlton et al. reports on two separate Italian
cohorts) (Charlton et al., 2015), were included (Fig. 1). Interrater re-
liability with respect to selected articles was considered good (inter-
rater agreement: 96%, kappa: 0.66 (95%CI: 0.62–0.70).
3.2. Study characteristics
Prevalence data for antidepressant use in the perinatal period was
provided for a total sample of 14,072,251 pregnancies from 15 high-
income countries. Sample size per cohort ranged between 436 and
1,895,519 pregnancies. Thirty-five cohorts (87.5%) were retrospective
in nature. Fifteen cohorts included data on the year before conception,
all 40 cohorts focused on the pregnancy period itself (either on the
complete pregnancy or on one or more trimesters) and eight cohorts
included data from the first postpartum year. Most cohorts included
information on SSRIs (k = 39), while some also focused on SRNIs
(k = 12), TCAs (k = 15), MAOi (k = 4) or other forms of anti-
depressants (k = 12). Prevalence rates were reported across a 26-year
period (from 1989 to 2015). Detailed characteristics of all cohorts are
provided in Supplementary Table 1 and 2 in the Online Resource.
3.3. Prevalence estimates per perinatal phase for all major antidepressant
groups
Fig. 2 presents the international random-effects prevalence esti-
mates for all major antidepressant groups before, during, and after
pregnancy. SSRIs were most often prescribed and examined (prevalence
ranging from 3.01% to 4.66%), followed by SNRIs (prevalence ranging
from 0.55% to 0.73%) and TCAs (prevalence ranging from 0.38% to
0.62%). Only two cohorts reported on MAOIs. SSRIs showed a small
decrease in prevalence from preconception to pregnancy (from 3.50%
to 3.01%) with a subsequent increase from pregnancy to the post-
partum period (3.01%–4.66%). These fluctuations did not reach sta-
tistical significance (Q-value = 4.60; df = 2; p-value = 0.10). Forest
plots of SSRI prevalence per perinatal phase can be found in the Online
Resource (Supplementary Figs. 1–3). Prediction intervals were wide
due to substantial heterogeneity.
3.4. Prevalence estimates of SSRIs during pregnancy
Fig. 3 presents the international random-effects prevalence esti-
mates of SSRIs during pregnancy stratified by substantive variables. Out
of the 40 cohorts, 22 cohorts reported on the prevalence of SSRI use for
a specific trimester. Prevalence rates slightly decreased, albeit non-
significantly so, from 2.46% in the first trimester to 1.59% in the second
trimester, increasing to 1.84% in the third trimester (Q-value = 4.34;
df = 2; p-value = 0.11). The observed prevalence estimates per tri-
mester tend to be lower than the overall prevalence estimate during
complete pregnancy (3.01%). Women may discontinue or initiate SSRIs
during any given trimester and are therefore not always represented in
each separate trimester. Ten cohorts reported on prevalence rates per
specific SSRI. Highest SSRI prevalence rates were found for sertraline
(1.10%), followed by citalopram and fluoxetine (0.77% and 0.76%
respectively; Q-value = 121.25; df = 5; p-value <0.01).
3.5. Variation in prevalence estimates per geographical region
Fig. 4 represents the random-effects prevalence estimates of SSRIs
during pregnancy per geographical region. Prevalence rates were
lowest in Australasia, with an overall estimate of 1.35% (95%CI
0.20;2.50, prevalence interval 0.00;6.98). Three out of four Aus-
tralasian cohorts reported a rate equal to or lower than 0.65%. In
Europe, the overall estimate was slightly higher with 1.64% (95%CI
1.42;1.85, prevalence interval 0.79;2.48). Nine cohorts reported on
prevalence rates in Northern America, coming to an overall estimate of
5.46% (95%CI 4.83;6.10, prevalence interval 3.05;7.87). The study by
Cooper et al. (2007), reporting the prevalence in a cohort from 1999 to
2003, had the largest prevalence with 10.20%. The study by
Figueroa (2010), reporting on a cohort from 1997 to 2002, had the
lowest prevalence with 2.41%. Both of these studies had a high risk of
bias regarding their sample frame (Supplementary Fig. 4 in the Online
Resource). Differences between geographical regions were statistically
significant (Q-value = 126.19; df = 2; p-value <0.01).
3.6. Prevalence rates over time
Of all 40 cohorts, only two reported prevalence rates (including
numerator and denominator) over a series of subsequent calendar years
( Huybrechts et al., 2015; Molenaar et al., 2019). Twelve cohorts from
six countries mentioned prevalence rates in the first and last year of
their cohort (in percentages, without numerator and denominator,
therefore unsuitable for meta-regression). These prevalence rates are
presented in Table 1. The majority of cohorts (90%) with a start date
from 1992 to 2001 showed an increase in antidepressant use during
pregnancy over time. Andrade et al. (Andrade et al., 2016), studying a
cohort of 1,895,519 deliveries between 2001 and 2013, observed the
largest increase over time. In this cohort, the SSRI prevalence during
pregnancy increased from 1.7% in 2001 to 14.9% in 2010. In contrast,
cohorts with a start date from 2004 to 2010 either showed stabilization
or a slight decrease in antidepressant use during pregnancy over time.
Quantitative analysis using meta-regression can be found in the Online
Resource.
3.7. Risk of bias of the studies
Overall, included studies had a low risk of bias, often reporting on
large representative cohorts. The sample frame was considered in-
appropriate in 51.3% of the included studies. For example,
Boukhris et al. (2016) and Brown et al. (2017) predominantly included
women of lower socio-economic status, while Wichman et al. (2009)
only included women from a single hospital in one state. Sampling
method was a potential risk in 33.3% of the studies. For example,
Figueroa (2010) only included women with a hospitalized delivery. The
gross majority of the studies were considered low risk of bias with
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Fig. 1. PRISMA flow diagram of study inclusion
Fig. 2. Global prevalence estimates per perinatal phasea.
a Pooled prevalence rates and Q statistics calculated using random effect estimation. The I2 statistic could not be calculated for pooled estimates of two cohorts or less.
The Q statistic only reflects tested differences between categories with n > 1. b NA = Not Applicable
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regards to sample size, description of subjects and setting, and response
rate (Supplementary Figs. 4 and 5 in the Online Resource).
3.8. Sensitivity analysis
The overall prevalence estimates per type of antidepressant differed
substantially between random- and fixed-effect calculations. The pre-
valence estimate for SSRIs during pregnancy was 2.33% (95%CI
Fig. 3. Global random effects prevalence estimates of SSRIs during pregnancy stratified by substantive variablesa.
a Pooled prevalence rates and Q statistics calculated using random effect estimation.
Fig. 4. Prevalence estimates of SSRIs during pregnancy stratified by region.
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2.32;2.34) using fixed-effects and 3.01% (95%CI 2.29;3.74) using
random-effects calculations. For SNRIs, this was 0.35% (95%CI
0.34;0.36) and 0.73% (95%CI 0.54;0.92), and for TCAs 0.16% (95%CI
0.16;0.17) and 0.38% (95%CI 0.29;0.46) respectively.
The results of the sensitivity analysis for SSRI use during pregnancy
are presented in Supplementary Figure 6 (Online Resource).
Retrospective studies reported an almost four times higher prevalence
(3.19%) than prospective studies (0.93%; p-value <0.01). Exposure
defined by prescription/dispensing records showed an overall pre-
valence of 3.23%, while exposure based on self-report had a prevalence
rate of 1.53% (p-value = 0.02). No significant differences were seen in
prevalence between studies including livebirths only, singletons only,
or inclusion of consecutive pregnancies (p-values between 0.21 and
0.48). Prevalence estimates stratified by the quality assessment of an
appropriate sample frame indicated lower prevalence rates in appro-
priate sample frames (2.20%) compared to non-appropriate sample
frames (3.85%; p-value <0.01). Studies with a detailed description of
subjects and setting had a lower prevalence rate (3.02%) compared to
studies without (4.20%; p-value <0.01), although only two studies in
this analysis lacked a detailed description (Taylor et al., 2015;
Yamamoto-Sasaki et al., 2019).
Results of small-study assessment can be found in the Online
Resource (Supplementary Fig. 7).
4. Discussion
Our findings demonstrate that the international use of anti-
depressants in the perinatal period depends on geographical region,
type of antidepressant and certain methodological factors. SSRIs were
the most commonly used antidepressant during pregnancy, with an
international prevalence estimate of 3.0% (95% CI 2.3;3.7) across a 26-
year period (from 1989 to 2015). A qualitative increase in prevalence of
antidepressants during pregnancy was noted. The most striking differ-
ence in prevalence estimates arose when stratifying by geographical
region. While the countries in Europe and Australasia had pooled pre-
valence estimates of 1.6% and 1.3% respectively, Northern America
had a prevalence estimate of 5.5%. Unfortunately, no studies were
available from Eastern European countries, or from developing geo-
graphical regions such as the Middle East, Central Asia and the African
continent, perhaps as a result of the absence of central birth registers,
linking pharmacy to birth records.
The observed differences in prevalence estimates for antidepressant
use during pregnancy by geographical region may reflect differences in
the prevalence and/or severity of underlying mental disorders leading
to medication use. However, previous studies have demonstrated si-
milar lifetime prevalence rates in English-speaking high-income coun-
tries and European high-income countries (Steel et al., 2014). It is more
plausible that the geographical variations are due to local prescribing
behavior of medication in general as well as prescribing behaviors
specific to antidepressants. In addition, help-seeking behavior of the
population and the organization of health care likely contribute to
geographic variation in antidepressant use. For example, in the United
States psychotherapy is often associated with out of pocket expenses.
Moreover, people in the US use mental health services less than in other
developed countries, while these services are consistently more ex-
pensive in the US than in comparably wealthy OECD countries
(Sawyer and Sroczynski, 2016). The US has a lower number of psy-
chologists (0.93) and psychiatrists (7.79) per 100,000 population than
most comparable countries (31 psychologists and 18 psychiatrists per
100,000 on average) (Sawyer and Sroczynski, 2016). The bulk of
mental health services for people with depression are therefore pro-
vided in primary care settings, who prescribe 79% of antidepressant
medications (Barkil-Oteo, 2013). A survey amongst primary care phy-
sicians showed that two-thirds reported that they could not get out-
patient mental health services for patients due to provider shortages,
health plan barriers and lack of coverage, thereby affecting offered
treatment methods (Cunningham, 2009).
Studies with detailed information on type of SSRI observed that
sertraline was most frequently prescribed during pregnancy, followed
by citalopram and fluoxetine. Sertraline is recommended for use during
pregnancy by multiple guidelines due to its favorable profile during
lactation (Pinheiro et al., 2015). Fluoxetine is not recommended as first
choice due to its long half-life and presence in breastmilk. Use of par-
oxetine has been associated to an increased risk of congenital cardio-
vascular malformation, but this is not confirmed (Grigoriadis et al.,
2013b). In general, guidelines discourage switching during pregnancy,
even when using a non-preferred SSRI (Molenaar et al., 2018b).
When we stratified by definition of SSRI use, we found a higher
prevalence estimate for studies using pharmacy records (prescription/
dispensing data) compared to studies relying on self-report. There is
some evidence that self-reported psychiatric medication use is less ac-
curate (Haapea et al., 2010; Van den Brandt et al., 1991), as a result of
social desirability bias or self-stigmatization (Cotterchio et al., 1999;
Nielsen et al., 2008; Rauma et al., 2013), but a recent large population-
based study showed the opposite: a very good agreement between an-
tidepressant self-report and prescription data (Hafferty et al., 2018).
The observed difference might therefore rather reflect a difference in
included study population.
There was a trend for a decrease in prevalence for both SSRIs and
TCAs from preconception to pregnancy, persisting into the second tri-
mester. Many women are reluctant to continue antidepressants during
pregnancy, because of potential negative consequences for the fetus,
and express a preference for non-pharmacological treatment
(Battle et al., 2013). Additionally, providers may counsel women to
discontinue antidepressants in pregnancy due to fears of fetal exposure,
sometimes unfortunately at the expense of maternal health and safety
(Molenaar et al., 2018a). Approximately 50% of women therefore de-
cides to discontinue their medication, either shortly before pregnancy
or during their first trimester (Molenaar et al., 2019). Since anti-
depressants are often not initiated during pregnancy, this results in
lower prevalence rates in the second and third trimesters. But dis-
continuation patterns have changed over time, with fewer women
discontinuing their antidepressants in the more recent calendar years
(Molenaar et al., 2019). It is unclear whether this trend to continue
more often is initiated by clinicians or pregnant women themselves.
Table 1
Studies reporting prevalence rates of antidepressants during pregnancy over
time.
Study Start % End % Country AD type
Petersen (2011) 1992 0.8 2006 3.3 United
Kingdom
Overall
Andrade (2008) 1996 2.0 2005 7.6 USA Overall
1996 1.5 2005 6.2 SSRIs
Jimenez-Solem (2013) 1997 0.2 2009 3.2 Denmark Overall
Cooper (2007) 1999 5.7 2003 13.4 USA Overall
1999 2.9 2003 10.2 SSRIs
Molenaar (2019) 1999 0.8 2014 2.1 The
Netherlands
SSRIs
Huybrechts (2015) 2000 2.3 2010 2.6 USA SSRIs
Andrade (2016) 2001 1.7 2010 14.9 USA SSRIs
Charlton (2015) 2004 1.4 2009 1.8 Italy
(Tuscany)
SSRIs
Charlton (2015) 2004 1.4 2009 1.3 Italy (Emilia
Romagna)
SSRIs
Taylor (2015) 2005 7.7 2013 6.3 USA Overall
Hurault-Delarue (2018) 2005 2.0 2014 1.7 France Overall
Hanley (2014) 2010 6.7 2011 6.4 USA Overall
Andrade (2016) 2010 14.9 2013 10.8 USA SSRIs
Narratively reported prevalence rates in the start year and end year of the co-
hort. Studies are sorted on start date of reported cohort. Arrows indicate an
increase (green), stabilization (yellow) or decrease (red) of prevalence rates. A
difference <0.5% is regarded as stabilization.
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Current guidelines do not give clear recommendations regarding the
continuation or discontinuation of antidepressant maintenance treat-
ment throughout pregnancy (Molenaar et al., 2018a, 2018b), which is
remarkable given the high prevalence of antidepressant use. Multiple
recent studies in the general (non-pregnant) population showed equal
efficacy of psychotherapy to antidepressant continuation in remitted
patients (Bockting et al., 2018; Fava et al., 2004; Kuyken et al., 2015,
2008; Segal et al., 2010).
Lastly, we looked at prevalence rates over time. We used qualitative
trend analysis from twelve cohorts since the included studies had lim-
ited quantitative information on prevalence rates per subsequent ca-
lendar year. While substantial increases in prevalence rates were ob-
served in cohorts with a start date between 1992 and 2001, cohorts
with a start date from 2004 onwards showed a stabilization or even
small decrease in prevalence rates. This may indicate saturation of the
market or reflect public opinion on the safety and efficacy of anti-
depressants during pregnancy. In contrast, prevalence rates in the
general population were still rising in these later time periods
(Hafferty et al., 2019; Pratt et al., 2017). The latter may, however,
result both from an increased longer-term use by regular antidepressant
users driving much of the increased reported prevalence, and from an
increase in the aging population, who in general have a higher pre-
valence of antidepressant use (Pratt et al., 2017). Future studies are
encouraged to quantitatively assess prevalence rates of antidepressants
during pregnancy over time to adequately map longitudinal evolution
of prescribing behavior in an international setting.
Our study has several limitations. We restricted our inclusion to
articles written in English, and did not search grey literature, which
may have contributed to the absence of data from low- and middle-
income countries. We did not contact authors of excluded articles. In
the estimation of prevalence rates per trimester, some women might
have contributed information to multiple subgroups (when they con-
tinued medication throughout several trimesters), which under-
estimates the variation between groups. Furthermore, we found that
substantial heterogeneity remained unaccounted for throughout the
analyses, even after accounting for hypothetical contributors.
Prevalence intervals were wide, predicting high variability in future
studies.
The results of this meta-analysis indicate that antidepressant use
during pregnancy is prevalent, with substantial variability based on
geographical region and study population. Driving factors for geo-
graphical differences, such as health care service barriers and pre-
scribing behavior, have to be identified in order to improve treatment
management. Special emphasis should be placed on research examining
the effectiveness of antidepressant maintenance treatment during the
perinatal period to determine the justifiable prevalence rate of anti-
depressants. Furthermore, risks of discontinuation and use of other
treatment and preventive options such as psychological interventions
should be examined in rigorous trials. Only after we have an accurate
estimate of the risks and benefits to both the fetus and the mother with
continuation and discontinuation of antidepressants, as well as alter-
native therapies when discontinuing antidepressants, can we begin to
develop evidence-based clinical guidelines for women with mental
health illnesses and their providers.
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